查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138281

全球多形性膠質母細胞瘤市場-2022-2029

Global Glioblastoma Multiforme Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

多形性膠質母細胞瘤 (GBM) 的研發進展正在推動全球市場的增長。此外，全球多形性膠質母細胞瘤負擔的增加正在推動市場增長。

多形性膠質母細胞瘤 (GBM) 的研發不斷增加正在推動市場增長。

多形性膠質母細胞瘤 (GBM) 的研發不斷增加，正在推動全球市場增長。例如，根據 Clinical Trials.gov 的數據，目前有四項積極的研究旨在干預多形性膠質母細胞瘤 (GBM) 並取得成果。例如，美國國家癌症研究所 (NCI) 和 Agenus 聯合研究復發性膠質母細胞瘤，使用貝伐單抗治療，以及由百時美施貴寶贊助的由小野製藥共同開發的使用 Nivolumab 和替莫唑胺治療神經腫瘤的研究。這樣的例子。此外，弗吉尼亞聯邦大學和美國國家癌症研究所聯合開展了索拉非尼（Nexavar）、丙戊酸（Depakot）和西地那非（偉哥）三聯療法治療高級別膠質瘤的安全性和有效性。還包括驗證耐受性和有效性的研究。此外，還有 139 項研究正在等待結果，正在招募或已完成招募，目前處於活躍狀態。

高昂的研究成本和神經膠質瘤幹細胞對常規療法的耐藥性複發是市場增長的主要障礙。

然而，高昂的研究成本、GBM 的複發、膠質瘤幹細胞對常規療法的耐藥性、市售的 GBM 藥物的神經毒性以及由於 GBM 缺乏治療效果而導致的死亡率增加是限制市場的一些因素。抑制生長。

全球多形性膠質母細胞瘤 (GBM) 市場 - 行業分析。

多形性膠質母細胞瘤 (GBM) 市場報告根據包括波特五力、研發、流行病學、監管、定價和管道分析在內的各種行業因素對市場進行了深入分析。

COVID-19 影響分析

在 COVID-19 大流行期間，許多公司的生產工廠停工，COVID-19 限制影響了世界各地的運輸，影響了許多公司的供應鏈。此外，社會限制阻礙了常規成像和其他相關篩查，導致大多數早期 GBM 病例未被發現，對全球多形性膠質母細胞瘤 (GBM) 市場產生了負面影響。

這份研究報告將提供對大約 40 多個市場數據表、45 多個圖表和 200 頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 調查與研發
      • GBM 案件增加
      • 市場策略
    • 限制因素
      • 高昂的研究成本
      • GBM 復發
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學分析
  • 研發
  • 管道分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 藥品
    • 替莫唑胺
    • 貝伐單抗
    • 卡莫司汀
    • 其他
  • 免疫療法
  • 電場療法
  • 其他

第 8 章按分子類型

  • 低分子化合物
  • 生物製品

第 9 章給藥途徑

  • 口語
  • 腸胃外

第 10 章，最終用戶

  • 醫院和診所
  • 癌症治療中心
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 13 章公司簡介

  • Pfizer
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Genentech
  • Amgen
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries, Ltd.
  • Arbor Pharmaceuticals LLC.
  • Sun Pharmaceutical Industries, Ltd.
  • F. Hoffmann-Le Roche AG
  • Novartis

第14章 DataM

簡介目錄
Product Code: DMPH2127

Market Overview

Glioblastoma Multiforme Market is expected to grow at a high CAGR of 8.8% during the forecasting period (2022-2029).

Glioblastoma multiforme (GBM) is a malignant type of central nervous system tumor. Globally, GBM accounts for 54% of new gliomas and 45% of primary malignant tumors. GBM can be either intra tentorial (area located below tentorium cerebella) or supratentorial (area located above the tentorium cerebella). New treatments involve drugs that can be used alone or combined with radiotherapy and chemotherapy. Still, there are more chances of reappearance when compared with electric field therapy. Increased research and clinical trials in treating GBM through immunotherapy are expected to account for a significant market growth share.

Market Dynamics

The increasing research and development on glioblastoma multiforme (GBM) are fueling the global market growth. Also, the globally increasing burden of glioblastoma multiforme is pushthe market growth.

The increasing research and development on glioblastoma multiforme (GBM) fuel market growth.

The increasing research and development on the Glioblastoma multiforme (GBM) are fueling the global market growth. For instance, according to Clinical Trials.gov, currently, 4 studies are active and with results for the intervention of Glioblastoma multiforme (GBM); for instance, National Cancer Institute (NCI), Agenus Inc. collaborated study for the Recurrent Glioblastoma, treatment with bevacizumab, a study for Brain Neoplasms treatment with Nivolumab, Temozolomide sponsored by Bristol-Myers Squibb and collaborated by Ono Pharmaceutical Co. Ltd, a study on Adult Giant Cell Glioblastoma treatment with bevacizumab sponsored by Radiation Therapy Oncology Group and collaborated by National Cancer Institute (NCI) and another study to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar), valproic acid (Depakote), and sildenafil (Viagra), when used to treat high-grade glioma, a type of brain tumor sponsored by Virginia Commonwealth University in collaboration with National Cancer Institute (NCI). Furthermore, 139 studies are waiting for results and are either recruiting or have completed the recruitment and are currently active.

The high research expenditure and the reoccurrence of resistance of glioma stem cells against conventional therapies are major hurdles to market growth.

However, the high expenditure on the research, recurrence of GBM, the resistance of glioma stem cells against conventional therapies, neurotoxicity caused by commercialized drugs for GBM, and lack of GBM treatment efficacy lead to an increase in mortality rate may restrain the growth of the market.

Global Glioblastoma multiforme (GBM) Market-Industry analysis.

The glioblastoma multiforme (GBM) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the production plants of many companies were down, and transportation across the globe was affected due to COVID-19 restrictions affecting the supply chain of many companies. Moreover, due to the restriction on socializing, regular imaging and other related check-ups were not possible, leaving a majority of the early-stage GBM cases undetected, negatively impacting the glioblastoma multiforme (GBM) market globally.

Segment Analysis

The drug segment is predicted to dominate the glioblastoma multiforme (GBM) market throughout the forecast period (2022-2029)

Temozolomide is expected to account for significant growth in the market owing to the advantages offered by the drug, which include delayed progression without impacting the quality of life with fewer adverse effects of the molecule. Also, methylated or alkylated DNA in the structural anomalies of the drug will produce a good efficacy, thus leading to a higher preference for this drug over the other drugs. On the contrary, pipeline drugs are expected to be the fastest-growing segment during the forecast period due to fewer adverse effects in the adult patient base with the available drug options. For instance, a study sponsored by Bristol-Myers Squibb in collaboration with Ono Pharmaceutical Co. Ltd, titled "A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma" and is estimated to be completed on August 1, 2023.

Geographical Analysis

North America has command over the glioblastoma multiforme (GBM) market.

North America is estimated to have a large market share in the glioblastoma multiforme market over the forecast period (2022-2029); this is because of the increasing incidences of central nervous system cancers in the geriatric population. According to the study done by the National Brain Tumor Society, in 2022, 700,000 are with a primary brain tumor, and around 88,970 more will be diagnosed 2022. Furthermore, according to the ASCO estimation, in 2022, over 25,050 adult United States residents will be diagnosed with brain and spinal cord tumors, and over 4,170 American children under the age of 15 will be diagnosed with brain tumors by the end of 2022. Furthermore, the ASCO estimated that around 18,280 U.S. adults would die from primary cancerous brain and CNS tumors in 2022. Worldwide over 251,329 people died because of a brain tumor in 2020. Moreover, North America has the most advanced and robust healthcare infrastructure and better reimbursement policies, fueling its dominance over the global market during the forecast period.

Competitive Landscape

The key players operating in the global glioblastoma multiforme market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Novartis, and Pfizer. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global glioblastoma multiforme market. For instance, on 04 May 2022, Bristol Myers Squibb received European Commission approval for Opdivo (nivolumab) with chemotherapy as a first-line treatment for patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Pfizer

Overview

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio

The product portfolio of Pfizer for glioblastoma multiforme (GBM) has ZIRABEV Injection (bevacizumab-bvzr).

The Glioblastoma multiforme (GBM) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Increasing Cases of GBM
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Research Cost
      • 4.1.2.2. Reoccurrence of GBM
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Drugs
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.2.1. Temozolomide
      • 7.2.2.2. Bevacizumab
      • 7.2.2.3. Carmustine
      • 7.2.2.4. Others
  • 7.3. Immunotherapy
  • 7.4. Electric Field Therapy
  • 7.5. Others

8. By Type of Molecule

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule Segment
    • 8.1.2. Market Attractiveness Index, By Type of Molecule Segment
  • 8.2. Small Molecules
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Parenteral

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals and Clinics
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Cancer Treatment Centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Pfizer
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Genentech
  • 13.3. Amgen
  • 13.4. Merck & Co., Inc.
  • 13.5. Teva Pharmaceutical Industries, Ltd.
  • 13.6. Arbor Pharmaceuticals LLC.
  • 13.7. Sun Pharmaceutical Industries, Ltd.
  • 13.8. F. Hoffmann-Le Roche AG
  • 13.9. Novartis

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact